Exsilio Therapeutics

Executive Summary

Exsilio Therapeutics is a preclinical-stage gene therapy company developing one-time, potentially curative treatments for severe genetic disorders. Leveraging advanced viral vector and gene editing technologies, the company aims to correct or compensate for disease-causing mutations in both rare and more prevalent monogenic diseases. Founded in 2021 and headquartered in Boston, Exsilio has raised $82 million in funding, reflecting investor confidence in its platform. The company's pipeline remains undisclosed, but its focus on durable, single-administration therapies positions it to address significant unmet medical needs in genetic medicine. As Exsilio advances toward the clinic, key milestones include IND-enabling studies and potential initial clinical data readouts.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program40% success
• Q3 2026Preclinical Proof-of-Concept Data60% success
• Q4 2026Potential Partnership or Licensing Deal30% success